Moderna (MRNA) stock rose roughly 510% over the year to September 21, 2026, climbing from about $25 to about $173. The S&P ...

Investors who bought in before last month's big news may want to take profits right now, if not exit a Moderna position completely. In the meantime, barring any further clinical trial news, expect ...

Moderna has surged over 500% this year while its closest messenger RNA rival sits nearly flat, and a single late-October data presentation at ESMO could either cement the rally or erase it overnight.

Moderna’s personalized mRNA cancer program delivered a major five-year melanoma result: combined with Merck’s Keytruda, it reduced the risk of cancer recurrence or death by 49% compared with Keytruda ...

An mRNA flu vaccine that updates close to season has finally been approved. Its speed means nothing until officials move a decades-old strain deadline ...

Merck and Moderna build a custom mRNA vaccine for each melanoma patient from tumor mutations. The strategy stumbles in cancers lacking enough targets ...

Findings showed the study did not meet its primary endpoint of preventing CMV infection in seronegative participants. Vaccine efficacy against CMV infection was reported to be between 6% to 23% ...

Moderna Inc. stocks have been trading up by 13.31 percent after breakthrough vaccine data spurred strong investor optimism. Key Takeaways MRNA Traders Need Now FDA cleared Moderna’s updated 2026–2027 ...

One reason that analysts and doctors want to see the data is to better understand how well the personalized treatment works.

The 1907 building has housed Moderna, Sigilon Therapeutics and Solid Biosciences over the years. Alexandria is partnering with Beacon Communities on the residential conversion.

A coveted Presidential Symposium slot at Europe's top oncology congress just sent Moderna shares flying 9%, but the actual ...

Phase 3 data for intismeran autogene in the adjuvant treatment of patients with resected stage IIB-IV melanoma selected ...